Thank you, Chair. My questions will be for Dr. Ruel.
The letter that the Canadian Cardiovascular Society wrote to some parliamentarians was, I think, a significant warning. I just wanted to expand upon some of the points you made in that letter, as well as in your remarks today, particularly around the dosing intervals that have been approved by [Technical difficulty—Editor].